SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Harding Thomas C.

(Last) (First) (Middle)
C/O CLOVIS ONCOLOGY, INC.
5500 FLATIRON PARKWAY, SUITE 100

(Street)
BOULDER CO 80301

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
12/03/2020
3. Issuer Name and Ticker or Trading Symbol
Clovis Oncology, Inc. [ CLVS ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
5. If Amendment, Date of Original Filed (Month/Day/Year)
12/07/2020
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 1,976(1) I By wife
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy) (2) 09/01/2027 Common Stock 6,000 $76.65 I By wife
Stock Option (right to buy) (3) 01/31/2030 Common Stock 500 $8.29 I By wife
Restricted Stock Units (4) 03/01/2028 Common Stock 93 (7) I By wife
Restricted Stock Units (5) 02/01/2029 Common Stock 1,250 (7) I By wife
Restricted Stock Units (6) 01/31/2030 Common Stock 2,900 (7) I By wife
Explanation of Responses:
1. These shares were omitted from the reporting person's original Form 3, and also were omitted from two Forms 4 filed by the reporting person after his original Form 3 was filed.
2. On September 5, 2017, the reporting person was granted 6,000 options. The option vested as to 25% of the shares on September 1, 2018, and the remainder vests in substantially equal installments over the 36 months immediately following such date. These shares were omitted from the reporting person's original Form 3.
3. On January 31, 2020, the reporting person was granted 500 options. The option vested as to 25% of the shares on January 31, 2021, and the remainder vests in substantially equal installments over the 36 months immediately following such date. These shares were omitted from the reporting person's original Form 3.
4. On March 1, 2018, the reporting person was granted 297 Restricted Stock Units. 25% of such Restricted Stock Units vested on March 1, 2019, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. These shares were omitted from the reporting person's original Form 3.
5. On February 1, 2019, the reporting person was granted 2,500 Restricted Stock Units. 50% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests on February 1, 2021. These shares were omitted from the reporting person's original Form 3.
6. On January 31, 2020, the reporting person was granted 2,900 Restricted Stock Units. 25% of such Restricted Stock Units vests on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date. These shares were omitted from the reporting person's original Form 3.
7. Each Restricted Stock Unit represents the right to receive one share of Common Stock.
Remarks:
Senior Vice President and Chief Scientific Officer
/s/ Thomas C. Harding 02/19/2021
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.